Skip to content
Assyro AI
Back to Glossary
General

FDA(Food and Drug Administration)

FDA is the United States federal agency within the Department of Health and Human Services that authorizes drugs, biologics, and medical devices before marketing and regulates the safety and labeling of foods and cosmetics.

Usage Examples

  • We cannot ship investigational material until FDA has an IND in effect for the protocol.
  • FDA cleared the device through 510(k), so the marketing copy has to say cleared, not approved.
  • The application goes to FDA in eCTD; the paper set is for the internal archive only.

What is FDA (Food and Drug Administration)?

FDA is the United States federal agency within the Department of Health and Human Services that authorizes drugs, biologics, and medical devices before marketing and regulates the safety and labeling of foods and cosmetics.

FDA exists because the United States decided that safety and effectiveness must be demonstrated before a medical product reaches a patient, not reconstructed after harm. Congress established FDA inside the Department of Health and Human Services and gave it a statutory mission: promote public health by promptly and efficiently reviewing clinical research and taking appropriate action on the marketing of regulated products. FDA turns that mission into control over interstate commerce.

FDA's mission covers foods, human and veterinary drugs, medical devices, cosmetics, and protection from electronic product radiation, with tobacco products added by later legislation. FDA does not own every consumer-safety question: meat, poultry, and processed egg products sit with USDA, and alcohol beverages largely with the Alcohol and Tobacco Tax and Trade Bureau. Inside FDA, authority is split across product centers, so "FDA said" almost always means a specific center said it.

FDA is encountered in practice as a sequence of gates rather than a single approval event: an investigational exemption before human studies, an application before marketing, an electronic format the statute makes mandatory, establishment registration, inspection, and postmarket reporting. FDA reviewers decide from what the applicant actually filed, so completeness and format drive review timing as much as the underlying science does.

Not to be confused with

CDER
FDA is the agency; CDER is the center inside it that reviews drug applications. An NDA is filed with FDA and decided by CDER, so "FDA approval" of a small-molecule drug is in practice a CDER decision.
CBER
CBER, not CDER, handles vaccines, blood products, and cell and gene therapies. Same agency, different center, different application type, which is why the BLA route under the PHS Act does not track the NDA route under the FD&C Act.
CDRH
device submissions such as the 510(k) premarket notification go to CDRH under the device provisions of the FD&C Act. A device that is cleared has a different legal status from a drug that is approved; the two words are not interchangeable.
FD&C Act
the FD&C Act is the statute; FDA is the agency the statute establishes within HHS. Obligations are written into the Act and 21 CFR. FDA administers and enforces them, and cannot waive what the Act itself requires.

FDA obligations attach to the company, not to the product, and several of them start long before a marketing application exists.

What you must do

  1. 1Obtain an effective approval of an application before introducing or delivering a new drug into interstate commerce21 U.S.C. 355(a)
  2. 2Use the investigational-use exemption, implemented by FDA as the IND, to study an unapproved drug in humans before any approval exists21 U.S.C. 355(i)
  3. 3Report to FDA at least 90 days before introducing a device intended for human use into commercial distribution, if the establishment is required to register21 U.S.C. 360(k)
  4. 4Submit drug and biologic applications in the electronic format FDA specifies in final guidance, binding no earlier than 24 months after that guidance issues21 U.S.C. 379k-1(a)

Common mistakes

  • Using "FDA approved" for a cleared device

    510(k) is a premarket notification reported to FDA at least 90 days before commercial distribution, not an approval of an application under 21 U.S.C. 355. Labeling and promotional material that call a cleared device approved misstate its regulatory status and are a standard enforcement target.

  • Assuming FDA obligations begin at submission

    the exposure starts earlier: an unapproved drug reaches human subjects only through the investigational-use exemption at 21 U.S.C. 355(i), and device establishments carry registration and 90-day notification duties independent of any application. Teams that plan backwards from a filing date discover the earlier gates too late to keep the date.

  • Treating the eCTD guidance as advisory because it is guidance

    FDA guidance is normally nonbinding, but 21 U.S.C. 379k-1(a) makes the electronic format specified in that final guidance a statutory requirement for NDAs, INDs, ANDAs, and biologics applications. A submission that ignores the specified format is not a compliant submission, regardless of how complete the science is.

When This Matters

  • We cannot ship investigational material until FDA has an IND in effect for the protocol.
  • FDA cleared the device through 510(k), so the marketing copy has to say cleared, not approved.
  • The application goes to FDA in eCTD; the paper set is for the internal archive only.

Frequently Asked Questions

FDA regulates foods, human and veterinary drugs, medical devices, cosmetics, and protection from electronic product radiation, the categories named in its statutory mission at 21 U.S.C. 393(b); later legislation added tobacco products. Meat, poultry, and processed egg products sit with USDA, and alcohol beverages largely with the Alcohol and Tobacco Tax and Trade Bureau.

Related Use Cases

Related Regulatory Intelligence

Related Actions

Sources & References

Share this page
Agent CTA Background

Simplify Food and Drug Administration compliance

Book a Demo